Multiplikator forward rega marang pendapatan Citius Oncology Inc. (CTOR)
Citius Oncology, Inc. (CTOR) attracts leading oncologists through generous options to commercialize therapies, reinforcing the brand's status as a valuable niche expert. The projected market capitalization-to-revenue ratio demonstrates valuation dynamics where the 8.60 mark serves as a current indicator. The company is developing an immunotherapy-based cancer combat system by integrating Lymphir into treatment protocols for rare lymphomas.
Rincian analitis perusahaan Citius Oncology, Inc.
- rega saiki lan proyeksi nilai saham:
- rincian kapitalisasi pasar:
- rincian valuasi buku bisnis:
- statistik kawajiban utang lan likuiditas:
Utang marang Ekuitas Citius Oncology, Inc.|CTOR - Rasio tanggungan utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Citius Oncology|CTOR - Kewajiban utang agregat|Rasio utang marang kapitalisasi buku Citius Oncology Inc|CTOR - Utang jangka dawa|Utang jangka cendhak perusahaan Citius Oncology|Rasio cepet citiusonc.com
- rincian asil keuangan lan kelipatan valuasi:
CTOR - Penghasilan resik|Bathi sing dikarepake Citius Oncology, Inc.|CTOR - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep Citius Oncology, Inc.|CTOR - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Citius Oncology Inc|CTOR - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Citius Oncology|CTOR - Bathi resik saben saham sajroning taun lumaku|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan citiusonc.com|CTOR - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Citius Oncology, Inc.
- indikator volume dodolan lan pendapatan:
Ringkesan analisis perusahaan:CTOR (citiusonc.com)
Citius Oncology, Inc. (CTOR) maintains a stable workforce and retains leading biochemists, creating a foundation for future sales that directly impacts market expectations. By analyzing the company's forward P/S on GURU.Markets, an investor can view the ratio of market capitalization to expected revenue, allowing for an assessment of the asset's premium and the timely balancing of risks through the price action reflected in this chart.
Analisis pesaing
Multiplikator Forward P/S ONC (BeiGene Oncology)|Multiplikator Forward P/S Halozyme Corp HALO|RVMD: Multiplikator forward rega marang pendapatan|Ascentage Pharma Group (AAPG) - Multiplikator forward rega marang pendapatan|CG Oncology Therapeutics (CGON) - Rasio rega marang prakiraan pendapatan|Prakiraan rega marang pendapatan UroGen Pharma URGN|Rasio rega marang prakiraan pendapatan Bicara Bio|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Personalis Genomics PSNL|Multiplikator Forward P/S ERAS|Rasio rega marang pendapatan sing dikarepake DCTH|Y-mAbs Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Aura Biosciences Inc (AURA)|CADL: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan ARAY (Accuray Inc.)|SLS: Multiplikator Forward P/S|ACTU: Rasio rega marang pendapatan sing dikarepake|Rasio rega marang prakiraan pendapatan TuHURA Biosciences Inc.|TARA: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Fate Therapeutics (FATE)|Rasio kapitalisasi marang dodolan sing dikarepake Aadi Bioscience|Rasio rega marang prakiraan pendapatan TScan Therapeutics Inc TCRX|CSBR: Kapitalisasi marang prakiraan pendapatan|XBIT: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan CVM (cel-sci.com)|OSTX: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Radiopharm Theranostics Ltd (RADX)|ARTV (Artiva) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan ANL (Adlai Nortye)|Rasio rega marang prakiraan pendapatan Veru Pharma (VERU)|Multiplikator Forward P/S Tempest Tx (TPST)|Rasio rega marang prakiraan pendapatan xiliotx.com XLO|Enochian BioSciences - Rasio rega marang prakiraan pendapatan|Mural Oncology - Multiplikator Forward P/S|KAPA - Multiplikator Forward P/S|OnKure Therapeutics Inc (OKUR) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan CytoMed|Rasio rega marang prakiraan pendapatan curis.com|Multiplikator forward rega marang pendapatan Apollomics, Inc. (APLM)|Multiplikator Forward P/S THAR|Advanced Biomed Corp - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Genprex GNPX|Rasio kapitalisasi marang dodolan sing dikarepake Calidi Bio (CLDI)|sunshinebiopharma.com - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep xeneticbio.com|salariuspharma.com (SLRX) - Rasio rega marang prakiraan pendapatan|Purple Biotech Ltd. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan AON|Multiplikator Forward P/S BeiGene Ltd.|Rasio rega marang prakiraan pendapatan Checkpoint Therapeutics, Inc. (CKPT)|Multiplikator forward rega marang pendapatan Elevation Oncology, Inc. ELEV|Multiplikator Forward P/S ICAD (iCAD Inc.)|IKNA - Multiplikator forward rega marang pendapatan|NTBL: Multiplikator forward rega marang pendapatan|viracta.com (VIRX) - Multiplikator forward rega marang pendapatan|MorphoSys (MOR) - Rasio rega marang prakiraan pendapatan|NAYA Biosciences Corp (NAYA) - Multiplikator Forward P/S|AAPGV (Ascentage) - Multiplikator Forward P/S
